Choice and Interpretation of Statistical Tests Used When Competing Risks Are Present
Top Cited Papers
- 20 August 2008
- journal article
- statistics in-oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (24) , 4027-4034
- https://doi.org/10.1200/jco.2007.12.9866
Abstract
In clinical cancer research, competing risks are frequently encountered. For example, individuals undergoing treatment for surgically resectable disease may experience recurrence near the removed tumor, metastatic recurrence at other sites, occurrence of second primary cancer, or death resulting from noncancer causes before any of these events. Two quantities, the cause-specific hazard function and the cumulative incidence function, are commonly used to summarize outcomes by event type. Tests for event-specific differences between treatment groups may thus be based on comparison of (a) cause-specific hazards via a log-rank or related test, or (b) the cumulative incidence functions via one of several available tests. Inferential results for tests based on these different metrics can differ considerably for the same cause-specific end point. Depending on the questions of principal interest, one or both metrics may be appropriate to consider. We present simulation study results and discuss examples from cancer clinical trials to illustrate these points and provide guidance for analysis when competing risks are present.Keywords
This publication has 40 references indexed in Scilit:
- Sample size calculations in the presence of competing risksStatistics in Medicine, 2007
- Cumulative Incidence in Competing Risks Data and Competing Risks Regression AnalysisClinical Cancer Research, 2007
- The influence of competing-risks setting on the choice of hypothesis test for treatment effectBiostatistics, 2006
- Regression Modeling of Competing Risks Data Based on Pseudovalues of the Cumulative Incidence FunctionBiometrics, 2005
- A note on competing risks in survival data analysisBritish Journal of Cancer, 2004
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology DataJournal of the American Statistical Association, 1993
- Effect of unequal censoring on the size and power of the logrank and Wilcoxon types of tests for survival dataStatistics in Medicine, 1989
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988